Hosted on MSN19h
Novel Berberine Drug Cut HbA1c in Type 2 DiabetesMore participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. “Merilog ...
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Interesting Engineering on MSN13d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatmentThe FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
The versatile rare diseases drug venglustat came from Sanofi ... disease is likely to play well with investors. Sanofi’s decision to axe diabetes R&D means that it will end development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback